The FDA last week tentatively approved...

...Mylan's generic version of Bristol-Myers Squibb's Eliquis, meaning the drug cannot go to market until the companies' patent suit is resolved. Eliquis, a leading blood thinner, currently holds preferred status for 76% of covered lives.  

SOURCE: MMIT Analytics, as of 7/16/19